Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $16.50, but opened at $16.10. Telix Pharmaceuticals shares last traded at $16.12, with a volume of 13,152 shares traded.
Analysts Set New Price Targets
TLX has been the topic of several research analyst reports. Wedbush restated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, March 12th. Finally, HC Wainwright began coverage on Telix Pharmaceuticals in a report on Thursday. They set a "buy" rating and a $23.00 price target on the stock.
Check Out Our Latest Report on TLX
Telix Pharmaceuticals Trading Down 2.3%
The business has a fifty day simple moving average of $16.86 and a 200-day simple moving average of $16.96. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99.
Hedge Funds Weigh In On Telix Pharmaceuticals
A hedge fund recently bought a new stake in Telix Pharmaceuticals stock. Private Advisor Group LLC bought a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm bought 10,140 shares of the company's stock, valued at approximately $170,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
